



Scholars Research Library

Der Pharmacia Lettre, 2016, 8 (18):102-106
(<http://scholarsresearchlibrary.com/archive.html>)



Cytotoxic Activity Assay of Tinocrisposide from *Tinospora crispa* on Human Cancer Cells

Adek Zamrud Adnan¹, Muhammad Taher², Tika Afriani³, Dewi Imelda Roesma⁴
and Andani Eka Putra⁵

¹Faculty of Pharmacy, Andalas University, Padang 25163, Indonesia

²Department of Pharmacy, International Islamic University Malaysia, 25200 Kuantan, Malaysia

³Department of Pharmacy, Mohammad Natsir University, Bukittinggi 26136, Indonesia

⁴Department of Biology, Andalas University, Indonesia

⁵Medicinal Faculty, Andalas University, Indonesia

ABSTRACT

Tinospora crispa is a climber plant belonging to the family of Menispermaceae. This plant has been used traditionally in Indonesia to treat some diseases and conditions such as fever, malaria, rheumatism, diabetes, cholera and inflammation. The aims of this study was to investigate cytotoxic activity of tinocrisposide extracted from the plant against human cancer cell lines. Cytotoxic activity of tinocrisposide in interval dose of 100; 50; 25; 12.5; 6.25; 3.125 $\mu\text{g/mL}$ has been investigated on H1299 and MCF-7 cell lines and their effects were quantified spectrophotometrically with the 3-(4,5 dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide (MTT) assay at wavelength, λ 570 nm. Tinocrisposide in concentrations of 100; 50; 25; 12.5; 6.25; 3.125 $\mu\text{g/mL}$ has been treated against H1299 cell line and showed a percentage viability of 55.5; 67.70; 80.84; 81.09; 82.69; and 87.06% respectively, with IC_{50} 70.9 $\mu\text{g/mL}$, whereas on MCF-7 cell line showed percentage viability of 80.71; 89.30; 92.76; 96.01; 96.58, and 102.66% respectively, with $\text{IC}_{50} > 100$ $\mu\text{g/mL}$. It can be concluded that tinocrisposide has not shown any cytotoxic activity against H1299 and MCF-7 cell line, but it can be used as a chemopreventive agent toward those cell lines.

Keywords: Cytotoxic activity, MTT assay, tinocrisposide, *Tinospora crispa*

INTRODUCTION

Cancer is one of the leading cause of death all over the world. It is characterized by uncontrolled growth and spreading of normal cells in the body. International Agency for Research on Cancer (IARC), in 2012, has estimated that there would be 14.1 million new cancer cases per year, and it expected the number to rise to 22 million annually within the next two decades. The most common causes of cancer death were lung, liver, and stomach cancer [1]. Medicinal plants have had a long history in cancer treatment [2] and have been used to treat human diseases for centuries [3]. Thus, it is possible for medicinal plants to be used as potential sources for new anticancer drugs development [4].

Tinospora crispa is a climber plant which grows in the wild and covers large area from the Southwestern part of China to Southeast Asia, including Indonesia, Malaysia, Vietnam, Thailand and India. This bitter taste plant that locally known as brotowali [5, 6] has been used as traditional medicine in Indonesia, Malaysia and Thailand to treat fever, diabetes, cholera, rheumatism, reducing thirst, hypertension, low appetite and also used for protection from mosquito bites [5, 7]. Previous studies have reported that, the methanolic and aqueous extract of *T. crispa* displayed a dose-dependent cytotoxic effect on MCF-7, HeLa, Caov-3 cell lines with an IC_{50} value of 33.8, 165 and 100 $\mu\text{g/mL}$, respectively [8, 9].

T. crispa has been extensively studied chemically and it has been reported to contain flavonoid and quaternary alkaloids including apigenin, berberine, palmatine [10, 11], borapetol A and borapetol B, borapetoside A and borapetoside B, and picroretine [12].

From methanol extract of dried pulvered *T. crispa* stems, a furanoditerpen glycoside with a very bitter taste, tinocrisposide, (C₂₇H₃₆O₁₁) has been isolated [13]. It has been observed that tinocrisposide is one of the biological active ingredients in *T. crispa* stem extracts. Tinocrisposide have showed some biological activities such as analgetic, antidiabetes, anti-inflammatory [14], antimalarial and antihistamine [15]. However, there is no report available regarding its cytotoxic activity.

The aim of this study was to isolate and investigate the cytotoxic activity of the tinocrisposide from *Tinospora crispa* stems against non-small cell lung cancer (H1299) and breast cancer cell (MCF-7).

MATERIALS AND METHODS

General

IR spectra was measured on Perkin Elmer Spectrum One Fourier Transform Infrared Spectrometer (FT-IR). The UV spectra was obtained on a Shimadzu UV-1800 UV/VIS spectrophotometer. The GCMS spectra was recorded on GC-MS QP2010 SE using a RTX-5 MS column at The University of Islamic Indonesia, Sleman Yogyakarta. Column chromatography was performed on silica gel 60 and Sephadex LH-20 (GE Healthcare). Organic solvents and TLC plates were purchased from Merck, Germany.

Dulbecco's Modified Eagle Medium (DMEM), fetal bovine serum (FBS), penicillin-streptomycin and trypsin were purchased from GIBCO. Phosphate buffered saline (PBS) was purchased from Sigma-Aldrich Chemical Co. (St. Louis, USA). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was purchased from Calbiochem, USA. Dimethylsulfoxide (DMSO) was purchased from Fisher Chemical (Thermo Fisher Scientific, USA).

Plant material

Fresh *T. crispa* stem samples were collected from Lubuk Minturun, Padang, Indonesia. This plant was identified and authenticated by Dr. Nurainas at Department of Biology, Faculty of Science, Andalas University. A specimen was deposited in the Herbarium ANDA, University of Andalas.

Cell lines

H1299 and MCF-7 cells were purchased from American Type Culture Collection (ATCC), Virginia, USA.

Extraction and isolation

The dried and powdered stem (3.2 kg) of *T. crispa* was extracted using n-hexane and methanol successively via maceration process for 3 times in 3 days each at room temperature, and evaporated in vacuo by rotary evaporator. The methanol extracts (273 g) was dissolved in 5 % acetic acid for overnight, decanted and then partitioned, sequentially, with n-hexane and DCM. Each fraction was dried to yield n-hexane, DCM and water fractions. The water fraction was basified with ammonia until pH 9-10 and partitioned with DCM to obtain DCM base extract. The neutral (24.56 g) and base DCM extract (2.64 g) fractions were subjected to column chromatography over silica gel 60 using step gradient elution (1-15%) with mixture of DCM and MeOH. The fractions were combined on the basis of thin layer chromatography (Silica gel TLC- plate) evaluation. TLC was carried out using the mixture of MeOH and DCM (1:9) as mobile phase and the fractions with same R_f values were combined and further purified by column chromatography on Sephadex LH-20 using mixture of methanol and water as mobile phase to obtain tinocrisposide as white amorphous powder (17 mg).

Cytotoxic (MTT) Assay

The cytotoxic effect of the isolated compound on the growth of different human cancer lines was measured by MTT assay [16] with minor modification. A total of 2.0 x 10⁵ cells/well were seed into 96-well flat bottom tissue culture plate and then incubated until it reached confluence at 37 °C with 5% CO₂. Then, the cells were treated with different concentration of test compound (3.125–100 µg/mL) in DMSO and incubated for 24 hours at 37 °C with 5% CO₂. Then, supernatant was discarded and washed once with phosphate buffer saline (PBS). Then, 20 µL of MTT stock solution (5 mg/mL PBS) was added to each well and incubate for 4 hours in CO₂ incubator. A total of 100 µL of DMSO was added to each well to solubilize the water-insoluble purple formazan crystal and left at room temperature. The absorbance was measured at wavelength of 570 nm and reference wavelength of 630 nm with a microplate reader (TECAN infinite M200). The untreated cells were used as the control. The results were expressed as a percentage of average absorbance of treated cells when compared with untreated cells. The half maximal

growth inhibitory concentration (IC₅₀) was defined as the concentration of compound that caused a 50% reduction of cell viability. Viability of cells (%) was calculated using the following equation:

$$\text{Viability of cells (\%)} = [(A_{\text{Sample}} - A_{\text{Blank}}) / (A_{\text{Untreated}} - A_{\text{Blank}})] \times 100$$

Data Analysis

All data were expressed as means \pm standard deviation (SD) of result obtained from at least three independent experiments. One-way analysis of variance (ANOVA) followed by Dunnett post hoc test were used to assess differences between the treated and the control. A value of $P < 0.05$ was considered significant. The statistical package IBM SPSS Statistics Version 21 for Windows was used in the analysis.

RESULTS AND DISCUSSION

In this study, we used tinocrisposide as a test compound which was isolated from neutral and base DCM fractions of *Tinospora crispa* stems. The isolation process was conducted according to the method by Pachaly and Adnan [13]. The structures of the compound was identified spectroscopically and confirmed with previous data in literature.

The compound was identified by FTIR, UV spectrophotometry and analysed by GC-MS. Spectral data of compound a white amorphous powder, FTIR (KBr pellet) $\bar{\nu} \text{ cm}^{-1}$: 3411 is for O-H stretch, 1654 is for C=O stretch, 1708 is for γ -lactone, 2924 is for Ar-H, 1516, 1437 are for C=C, 874, 815, 760 are for C-H-Bending. UV λ_{max} in MeOH nm: 210. GC-MS fragmen (Retention time: 2.500): 83, 98, 238, 295, 310, 327.

MTT assay was conducted to determine the cytotoxic effects of compound on H1299 and MCF-7 cell lines. The cell lines were incubated to various concentrations for 24 hours and cytotoxicity was determined using a microplate reader. Meanwhile, the inhibition concentration (IC₅₀) value was determined from the linear regression of the experimental data.

Based on the results of the study (Table 1), tinocrisposide did not show any cytotoxic activity against H1299 cell with IC₅₀ 70.9 $\mu\text{g/mL}$ and MCF-7 cell with IC₅₀ values $>100 \mu\text{g/mL}$ (Fig. 1).

Figure 2 showed the H1299 cell lines treated with different concentration (3.125, 6.25, 12.5, 25, 50 and 100) $\mu\text{g/mL}$ of tinocrisposide observed under the phase-contrast inverted microscope. The highest concentration of compound, 100 $\mu\text{g/mL}$ (F) causes cell death. As the concentration of sample decrease, the viable cells will be increased. Thus, at the lowest concentration, 3.125 $\mu\text{g/mL}$ (A), most of the cells were still attached and interacting with the neighboring cells. In contrast, compound concentration used did not affect the cell viability of MCF-7 cell lines even high concentration used (Figure not shown), where the cells were still attached and interacting with neighboring cells.

Table 1. Effect of tinocrisposide on cell viability

Concentration	Average of % viability	
	H1299	MCF-7
3.125	87.06 \pm 9.59	102.66 \pm 8.26
6.25	82.69 \pm 6.84	96.58 \pm 3.68
12.5	81.09 \pm 8.27	96.01 \pm 1.01
25	80.84 \pm 4.98	92.76 \pm 1.94
50	67.70 \pm 4.62	89.30 \pm 0.62
100	55.5 \pm 1.94	80.71 \pm 3.67

Values are expressed as mean \pm SD, n=3

Table 2. Cytotoxicity data (IC₅₀ value in $\mu\text{g/mL}$) of tinocrisposide

Cell lines	IC ₅₀
H1299	70.9
MCF-7	>100




Figure 1. Cytotoxic activity of tinocrisposide. Untreated cells was used as negative control. Error bars represent standard deviation of triplicate values. Asterisks represent statistically significant (p value < 0.05) data as compared to untreated cells




Figure 2. H1299 cells treated with different concentration of tinocrisposide, (A) 3.125 µg/mL (B) 6.25 µg/mL (C) 12.5 µg/mL (D) 25 µg/mL (E) 50 µg/mL and (F) 100 µg/mL observed under the phase-contrast inverted microscope with magnification of 20x

CONCLUSION

It is concluded that tinocrisposide from *Tinospora crispa* stem has not shown any cytotoxic activity against H1299 (IC₅₀ 70.9 µg/mL) and MCF-7 cell (IC₅₀ values > 100 µg/mL), but it can be used as a chemopreventive agent.

REFERENCES

- [1] J Ferlay; I Soerjomataram; M Ervik; R Dikshit; S Eser, C Mathers; M Rebelo; DM Parkin; D Forman; F Bray. Estimated cancer incidence, mortality and prevalence worldwide in **2012**, GLOBOCAN, International Agency for Research on cancer. Lyon, France, **2013**.
- [2] R Jain; SK Jain. *Asian Pacific Journal of Tropical Biomedicine*, **2011**, 1, 147–150.
- [3] JVC Sharma; G Pitchaiah; D Satyavati; JV Rao; H Sanja. *International Journal of Research in Pharmaceutical and Biomedical Sciences*, **2011**, 2(2), 760–764.
- [4] E Caamal-Fuentes; LW Torres-Tapia; P Simá-Polanco; SR Peraza-Sánchez; R Moo-Puc. *Journal of Ethnopharmacology*, **2011**, 135(3), 719–724.
- [5] AC Dweck; JP Cavin. Andawali (*Tinospora crispa*): A review. *Personal Care Magazine*, **2006**, 33–39.
- [6] NM Mohamad; HA Zin; P Wahab, SF Ibrahim; AS Sulaiman; SS Zahariluddin. *Journal of Ethnopharmacology*, **2011**, 133, 1021–1026.
- [7] B Kongsaktrakoon; R Temsiririrkkul; W Suvitayavat; S Nakornchai; Y Wongkrajang. *Journal of Pharmaceutical Sciences*, **1994**, 21(1), 1–6.
- [8] GA Froemming. *Biomedical Research*, **2011**, 22(1), 57–62.
- [9] A Zulkhairi; MA Abdah; NH Kamal; L Nursakinah, MAM Moklas; F Fazali, FA Khairunnur; KAK Kamilah; MS Zamree; MMA Shahidan. *Malaysian Journal of Nutrition*, **2008**, 14(2), 173–187.
- [10] Y Umi Kalsom; H Noor. *Fitoterapia*, **1995**, 66(3), 280.
- [11] BC Bisset; MK Nwaiwu. *Planta Medica*, **1984**, 48, 275–279.
- [12] AK Pathak, DC Jain, RP Sharma. *International Journal of Pharmacognosy*, **1995**, 33(4), 277–287.
- [13] P Pachaly; AZ Adnan. *Archive Der Pharmazie*, **1992**, 325(11), 705–708.
- [14] AZ Adnan; M Husni; A Almahdy. *Warta Tumbuhan Obat Indonesia*, **1998**, 4(2), 9–12.
- [15] AZ Adnan. Biological activity study of Tinocrisposide and *Tinospora crispa* Miers, Andalas University Press, Padang, Indonesia, **2012**.
- [16] T Mosmann. *Journal of Immunological Methods*, **1983**, 65(1-2), 55–63.